Personalized Cancer Vaccine Cuts Melanoma Risk 42%

A personalized cancer vaccine just posted the kind of result oncologists have waited years to see. Merck and Moderna say their mRNA shot, called intismeran, cut the risk of melanoma returning or the patient dying by forty-two percent when paired with an immunotherapy drug, according to Nature.

What the trial actually found

The phase three study enrolled one thousand one hundred and thirty-seven people with moderate to advanced melanoma across one hundred and fifty-seven centres. Everyone received pembrolizumab, sold as Keytruda, which is already a standard immunotherapy. About two thirds also got the vaccine, while the rest got a placebo, according to the BBC.

After roughly two years, the vaccine group was far less likely to see the cancer come back. The BBC reports the combination also reduced the risk of the disease spreading by thirty-eight percent compared with immunotherapy alone. Trial leader Georgina Long told Nature that participants had been followed for around twenty-five months and that the therapy caused no major harmful side effects.

How a personal cancer vaccine works

This cancer vaccine is not a shot that stops you from getting skin cancer. It is built for people who have already had their tumour removed by surgery and want to keep it from returning. Researchers sequence DNA from each patient's tumour to find mutations that produce proteins called neoantigens, which help the immune system tell cancer cells from healthy ones.

Those targets are then written into mRNA, the same family of technology used in some Covid jabs. The result is a one-of-one vaccine that trains your immune system to recognise your own cancer if it ever shows up again. That personalization is exactly why the process is hard to scale, since every dose has to be custom made.

Why scientists are hyped, and cautious

Nature notes that oncologists treat a ten percent risk reduction as substantial. Seth Cheetham, a geneticist at the University of Queensland, said a cut of more than forty percent would send many researchers over the Moon. That is a big deal for a field that has chased this idea for years.

Still, nobody is calling it a cure. Professor Alan Melcher of the Institute of Cancer Research in London called the results very impressive, but warned against getting ahead of the evidence. He said one melanoma trial cannot prove the same approach works across all cancers, and that longer follow-up is needed to show whether patients live longer overall.

Jessamy Tiffen, a cancer geneticist in Sydney, added that some people did not respond to the vaccine and that cancer cells are good at adapting. The full data are due at the European Society for Medical Oncology meeting in Madrid on October twenty-fourth, and they have not yet been peer reviewed in a journal.

The leak, the stock drop and what comes next

The numbers surfaced online on October twenty-second, which pushed the companies to release their key results early. Moderna shares, which had climbed since August, fell by around twenty-five percent, according to Nature. Analysts quoted by the BBC said the results were not quite as strong as an earlier, much smaller trial.

One analyst told Forbes the sell-off reflected inflated expectations rather than a true verdict on the treatment. Both companies say they are engaging with regulators, which suggests they could file for approval as soon as next year. If cleared, it could become the first approved mRNA cancer vaccine.

The same approach is already being tested in kidney, bladder and lung cancers. Cost will matter too, because each patient needs a genetic analysis of their tumour and a vaccine made just for them. Public health systems like the NHS will have to decide whether that price is worth it.

What it means for you

Nothing changes at your doctor's office today. But the signal is strong: personalized medicine is moving from lab promise to late-stage proof. For patients like Tony Chapman, seventy-five, who joined the trial after his melanoma came back and is now cancer free three years on, that proof is personal. For more on the science stories we are tracking, check our health coverage.